Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New injection shows promise for tough lymphoma cases

NCT ID NCT06970496

First seen Nov 20, 2025 · Last updated May 19, 2026 · Updated 32 times

Summary

This early-stage trial tests a new drug called B019 in 48 people whose B-cell non-Hodgkin's lymphoma has returned or not responded to other treatments. The main goal is to check safety and find the right dose, while also seeing if it shrinks tumors. Participants must have a specific type of lymphoma and be in fair health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jiangxi Cancer Hospital

    Nanchang, China

    Contact

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

    Contact

  • Shanghai General Hospital

    Shanghai, China

    Contact

  • Sun Yat-sen University Cancer Center

    Guangzhou, China

    Contact

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China

    Contact

  • Xijing Hospital

    Xi'an, China

    Contact

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, China

    Contact

Conditions

Explore the condition pages connected to this study.